Angiotensin-converting enzyme genotype interacts with systolic blood pressure to determine coronary heart disease risk in healthy middle-aged men

Hypertension

Volumn 50, Issue 2, 2007, Pages 348-353

  Muthumala, Amal ^a   Montgomery, Hugh ^a   Palmen, Jutta ^a   Cooper, Jackie A ^a   Humphries, Steve E ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

ACE gene; CHD; Genetics association studies; Hypertension; Risk factors; Systolic

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE;

ADULT; ALLELE; ARTICLE; CONTROLLED STUDY; GENE INTERACTION; GENETIC ASSOCIATION; GENOTYPE; HOMOZYGOTE; HUMAN; ISCHEMIC HEART DISEASE; MALE; NORMAL HUMAN; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; SYSTOLIC BLOOD PRESSURE;

CHI-SQUARE DISTRIBUTION; COHORT STUDIES; CONFIDENCE INTERVALS; CORONARY DISEASE; FOLLOW-UP STUDIES; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; GREAT BRITAIN; HUMANS; HYPERTENSION; INCIDENCE; MALE; MIDDLE AGED; PEPTIDYL-DIPEPTIDASE A; PROPORTIONAL HAZARDS MODELS; REFERENCE VALUES; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SYSTOLE;

EID: 34547620106     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.107.086843     Document Type: Article

References (35)

1. Campbell DJ. Circulating and tissue angiotensin systems. J Clin Invest. 1987;79:1-6.
2. Morishita R, Gibbons GH, Ellison KE, Lee W, Zhang LN, Yu H, Kaneda Y, Ogihara T, Dzau VJ. Evidence for direct local effect of angiotensin in vascular hypertrophy - in-vivo gene-transfer of angiotensin-converting enzyme. J Clin Invest. 1994;94:978-984.
3. Rajagopalan S, Kurz S, Munzel T, Tarpey M, Freeman BA, Griendling KK, Harrison DG. Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation - contribution to alterations of vasomotor tone. J Clin Invest. 1996;97:1916-1923.
4. Rigat. B., Hubert. C., Alhenc-Gelas. F, Cambien. F, Corvol. P., Soubrier. F. An insertion deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest. 1990;86:1343-1346.
5. Danser AHJ, Schalekamp MADH, Bax WA, van den Brink AM, Saxena PR, Riegger GAJ, Schunkert H. Angiotensin-converting enzyme in the human heart : effect of the deletion/insertion polymorphism. Circulation. 1995;92:1387-1388.
6. Cambien F, Poirier O, Lecerf L, Evans A, Cambou JP, Arveiler D, Luc G, Bard JM, Bara L, Ricard S, Tiret L, Amouyel P, Alhenc-Gelas F, Soubrier F. Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction. Nature. 1992;359:641-644.
7. Agerholm-Larsen B, Nordestgaard BG, Tybjarg-Hansen A. ACE gene polymorphism in cardiovascular disease: meta-analyses of small and large studies in whites. Arterioscler Thromb Vasc Biol. 2000;20:484-492.
8. Morgan TM, Coffey CS, Krumholz HM. Overestimation of genetic risks owing to small sample sizes in cardiovascular studies. Clin Genet. 2003;64:7-17.
9. Sayed-Tabatabaei FA, Schut AFC, Arias Vasquez A, Bertoli-Avella AM, Hofman A, Witteman JCM, van Duijn CM. Angiotensin converting enzyme gene polymorphism and cardiovascular morbidity and mortality: the Rotterdam Study. J Med Genet. 2005;42:26-30.
10. Schut AFC, Bleumink GS, Stricker BHC, Hofman A, Witteman JCM, Pols HAP, Deckers JW, Deinum J, van Duijn CM. Angiotensin converting enzyme insertion/deletion polymorphism and the risk of heart failure in hypertensive subjects. Eur Heart J. 2004;25:2143-2148.
11. Talmud PJ, Flavell DM, Alfakih K, Cooper JA, Balmforth AJ, Sivananthan M, Montgomery HE, Hall AS, Humphries SE. The lipoprotein lipase gene serine 447X stop variant influences hypertension-induced left ventricular hypertrophy and risk of coronary heart disease. Clin Sci. 2007;112:617-624.
12. Gable DR, Stephens JW, Cooper JA, Miller GJ, Humphries SE. Variation in the UCP2-UCP3 gene cluster predicts the development of type 2 diabetes in healthy middle-aged men. Diabetes. 2006;55:1504-1511.
13. O'Dell SD, Humphries SE, Day INM. Rapid methods for population-scale analysis for gene polymorphisms - the ace gene as an example. Br Heart J. 1995;73:368-371.
14. Tanaka C, Kamide K, Takiuchi S, Miwa Y, Yoshii M, Kawano Y, Miyata T. An alternative fast and convenient genotyping method for the screening of angiotensin converting enzyme gene polymorphisms. Hypertension Res. 2003;26:301-306.
15. Harrison DG, Cai H, Landmesser U, Griendling KK. Interactions of angiotensin II with MAD(P)H oxidase, oxidant stress and cardiovascular disease. J Renin Angiotensin Aldosterone Syst. 2003;4:51-61.
16. Ferrario CM, Strawn WB. Role of the renin-angiotensin-aldosterone system and proinflammatory mediators in cardiovascular disease. Am J Cardiol. 2006;98:121-128.
17. Graninger M, Reiter R, Drucker C, Minar E, Jilma B. Angiotensin receptor blockade decreases markers of vascular inflammation. J Cardiovasc Pharmacol. 2004;44:335-339.
18. Tsikouris JP, Cox CD. Pharmacologic blockade of the renin-angiotensin system: Vascular benefits beyond commonly understood pharmacologic actions. Pharmacotherapy. 2003;23:1141-1152.
19. Strauss MH, Hall AS, Tsuyuki RT, McDonald MA. Angiotensin receptor blockers may increase risk of myocardial infarction: unraveling the ARB-MI paradox. Circulation. 2006;114:838-854.
20. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000;342:145-153.
21. Reja V, Goodchild AK, Phillips JK, Pilowsky PM. Upregulation of angiotensin AT1 receptor and intracellular kinase gene expression in hypertensive rats. Clin Exper Pharmacol Physiol. 2006;33:690-695.
22. Zhou MS, Adam AG, Jaimes EA, Raij L. In salt-sensitive hypertension, increased superoxide production is linked to functional upregulation of angiotensin II. Hypertension. 2003;42:945-951.
23. Zhou MS, Schulman IH, Pagano PJ, Jaimes EA, Raij L. Reduced NAD(P)H oxidase in low renin hypertension: link among angiotensin II, atherogenesis, and blood pressure. Hypertension. 2006;47:81-86.
24. Li JM, Gall NP, Grieve DJ, Chen MY, Shah AM. Activation of NADPH oxidase during progression of cardiac hypertrophy to failure. Hypertension. 2002;40:477-484.
25. Wenzel S, Taimor G, Piper HM, Schlueter KD. Redox-sensitive intermediates mediate angiotensin II-induced p38 MAP kinase activation, AP-1 binding activity, and TGF-beta expression in adult ventricular cardiomyocytes. Faseb J. 2001;15.
26. Estacio RO, Jeffers BW, Havranek EP, Krick D, Raynolds M, Schrier RW. Deletion polymorphism of the angiotensin converting enzyme gene is associated with an increase in left ventricular mass in men with type 2 diabetes mellitus. Am J Hypertens. 1999;12:637-642.
27. Montgomery HE, Clarkson P, Dollery CM, Prasad K, Losi MA, Hemingway H, Statters D, Jubb M, Girvain M, Varnava A, World M, Deanfield J, Talmud P, McEwan JR, McKenna WJ, Humphries S. Association of angiotensin-converting enzyme gene I/D polymorphism with change in left ventricular mass in response to physical training. Circulation. 1997;96:741-747.
28. Lechin M, Quinones MA, Omran A, Hill R, Yu QT, Rakowski H, Wigle D, Liew CC, Sole M, Roberts R, Marian AJ. Angiotensin-I converting enzyme genotypes and left ventricular hypertrophy in patients with hypertrophic cardiomyopathy. Circulation. 1995;92:1808-1812.
29. Iwai N, Ohmichi N, Nakamura Y, Kinoshita M. Dd-genotype of the angiotensin-converting enzyme gene is a risk factor for left-ventricular hypertrophy. Circulation. 1994;90:2622-2628.
30. Levy D, Anderson KM, Savage DD, Kannel WB, Christiansen JC, Castelli WP. Echocardiographically detected left-ventricular hypertrophy-prevalence and risk-factors-the Framingham Heart-Study. Ann Intern Med. 1988;108:7-13.
31. Haider AW, Larson MG, Benjamin EJ, Levy D. Increased left ventricular mass and hypertrophy are associated with increased risk for sudden death. J Am Coll Cardiol. 1998;32:1454-1459.
32. Panahloo A, Andres C, Mohamed-Ali V, Gould MM, Talmud P, Humphries SE, Yudkin JS. The insertion allele of the ACE gene I/D polymorphism: a candidate gene for insulin resistance? Circulation. 1995;92:3390-3393.
33. Heimann AS, Favarato MH, Gozzo FC, Rioli V, Carreno FR, Eberlin MN, Ferro ES, Krege JH, Krieger JE. ACE gene titration in mice uncovers a new mechanism for ACE on the control of body weight. Physiol Genomics. 2005;20:173-182.
34. Arnett DK, Claas SA, Glasser SP. Pharmacogenetics of antihypertensive treatment. Vasc Pharmacol. 2006;44:107-118.
35. Humphries SE, Hawe E, Dhamrait S, Miller GJ, Talmud PJ. In search of genetic precision. Lancet. 2003;361:1908-1909.